Can cord blood t cells be trained to stop viral infections after transplant?

NCT ID NCT03594981

Ongoing Disease control Sponsor: Catherine Bollard Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial is testing whether specially grown T cells from cord blood can help prevent or treat infections caused by common viruses (CMV, EBV, BKV, and adenovirus) in people who have had a cord blood transplant. The study aims to find the safest and most effective dose of these virus-specific T cells. Participants receive an intravenous infusion of the cells, and researchers monitor for side effects and how long the cells survive in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: donor-derived cytotoxic T lymphocytes (CTLs) specific for CMV, EBV, BKV, and adenovirus
What this could lead to: If successful, this could offer a way to prevent or treat serious viral infections after cord blood transplants, potentially improving survival and reducing complications.
What could go wrong: This is an early-phase trial with a small number of participants, so the optimal dose and safety are still being determined. There is a risk of side effects like graft-versus-host disease or the cells not working as expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOVIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoviridae infectious disease BK-virus nephropathy cytomegalovirus infection Epstein-Barr virus infection viral infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VIRAL INFECTION

Contacts and locations

Locations

Children's National Health System

Washington D.C., District of Columbia, 20010, United States
M.D. Anderson Cancer Center (MDACC)

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.